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Background: The aim of this study was to evaluate the incidence and mortality of prostate cancer and
their relationship with the Human Development Index (HDI) and its components in Asia in 2012.
Methods: This study was an ecological study conducted based on the GLOBOCAN project of the World
Health Organization. The correlation between standardized incidence rate (SIR) and standardized mor-
tality rate (SMR) of prostate cancer with HDI and its components was assessed using SPSS Inc Version
18.0 (Chicago).
Results: There were 1,094,916 incident cases of prostate cancer and 307,481 deaths recorded in 2012
worldwide. SIR and SMR due to HDI were 72 and 9.7 in very high human development regions, 37.5 and
12.9 in high human development regions, 7 and 3.7 in medium human development regions, and 14.9
and 12.1 in low human development regions per 100,000 people, respectively. A positive correlation of
0.475 was seen between SIR of prostate cancer and HDI (P  0.001). Also, a negative correlation of 0.160
was seen between SMR of prostate cancer and HDI (P ¼ 0.032).
Conclusion: The incidence of prostate cancer is high in countries with higher development. A positive
correlation was observed between the SIR of prostate cancer and the HDI and its components, such as life
expectancy at birth, mean years of schooling, and the gross national income per capita. In addition, there
was a negative correlation between SMR and HDI.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently, cancer is one of the leading causes of death in many
high-income countries.1 Prostate cancer is one of themost common
cancers among men.2e5 Deaths from prostate cancer are second
highest after deaths from lung cancer.6 The incidence and preva-
lence of prostate cancer vary in different parts of the world, with
the highest in North America and the lowest in South Asia.7 It is
estimated that 1.1 million men with prostate cancer were diag-
nosed in 2012 and 70% of them (795,000 cases) were in developedcal Sciences, Zabol, Iran and
ol of Public Health, Tehran
iya).
ciﬁc Prostate Society, Published bcountries.8 The highest age-speciﬁc incidence rate in New Zealand
and Australia is 111.6 per 100,000 and the lowest rate is in South
Asia with a level of 4.5 per 100,000.3,7
Several studies have shown that the incidence of prostate cancer
in recent years has grown substantially.9e11 The increase in the
incidence of prostate cancer could be due to greater access to
prostate-speciﬁc antigen (PSA) diagnostic tests by communities
and other factors such as lifestyle, nutrition, physical activity,
environmental factors, and smoking.12e15 The PSA test that started
in 1980 has caused a signiﬁcant increase in the incidence of pros-
tate cancer.16 Studies have shown that countries with higher social
and economic levels have higher levels of prostate cancer; in
contrast, prostate cancer is seen less often in countries with lower
socioeconomic levels.17 It has been observed that incidence of this
illness increases with age, and it is thought that the aging of they Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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incidence of this disease in the future.18e20
The effect of aging in low- and middle-income countries is
greater than in high-income countries. It is predicted that therewill
be 20.3 million new cases of prostate cancer in 2030 and that 13.2
million of them will not survive. In 2008, there were 12.7 million
new cases, 7.6 million of these died.21
Economic and social levels are known to affect the incidence
andmortality of cancer.22 The Human Development Index (HDI) is a
predictor of the economic and social level of different countries that
can be associated with many diseases, including cancer.17,23e25
Several studies have examined the role of the HDI and its rela-
tionship with the incidence andmortality of cancer.4,17,26 Due to the
probable role of HDI in changing the incidence and prevalence of
prostate cancer and the importance of knowledge about the inci-
dence and prevalence of this disease in programming and per-
forming etiology studies, and lack of an integratedworldwide study
of HDI, this study investigated the standardized incidence rate (SIR)
and standardized mortality rate (SMR) of prostate cancer and their
relationship with HDI in 2012.
2. Materials and methods
2.1. Method for estimating age-speciﬁc incidence and mortality
rates in the global cancer project by the international agency for
research on cancer
This was a global ecologic study to assess the correlation be-
tween the age-speciﬁc incidence and mortality rate and the HDI,
and its particulars, including life expectancy at birth, mean years of
schooling, and gross national income per capita. Data about the
age-speciﬁc incidence andmortality rates for every country in 2012
were obtained from the global cancer project (http://globocan.iarc.
fr/Default.aspx),27 and the HDI from the Human Development
Report 2013,28 which includes information about the HDI for every
country in 2012.
2.2. Estimate of age-speciﬁc incidence rate
The methods of estimation are country speciﬁc, and the quality
of the estimation depends upon the quality and amount of infor-
mation available for each country. In theory, there are as many
methods as countries, and because of the variety and the
complexity of these methods, an overall quality score for the inci-
dence and mortality estimates combined is almost impossible to
establish. However, an alphanumeric scoring system that inde-
pendently describes the availability of incidence and mortality data
has been established at the country level. The combined score is
presented together with the estimates for each country with the
aim of providing a broad indication of the robustness of the
estimation.
The methods to estimate the sex- and age-speciﬁc incidence
rates of cancer for a speciﬁc country fall into one of the following
broad categories, in priority order: (1) rates projected to 2012 (38
countries); (2) most recent rates applied to 2012 population (20
countries); (3) estimates from national mortality by modeling, us-
ing incidence mortality ratios derived from recorded data in
country-speciﬁc cancer registries (13 countries); (4) estimates from
national mortality estimates by modeling, using incidence mor-
tality ratios derived from recorded data in local cancer registries in
neighboring countries (nine European countries); (5) estimates
from national mortality estimates using modeled survival (32
countries); (6) estimates as the weighted average of the local rates
(16 countries); (7) one cancer registry covering a part of a country is
used as representative of the country proﬁle (11 countries); (8) age/sex speciﬁc rates for all cancers were partitioned using data on
relative frequency of different cancers (by age and sex) (12 coun-
tries); and (9) rates are those of neighboring countries or registries
in the same area (33 countries).27
2.3. Estimate of age-speciﬁc mortality rate
Depending on the degree of detail and accuracy of the national
mortality data, six methods have been utilized in the following
order of priority: (1) rates projected to 2012 (69 countries); (2)
most recent rates applied to 2012 population (26 countries); (3)
estimates as the weighted average of regional rates (one country);
(4) estimates from national incidence estimates by modeling, using
country-speciﬁc survival (two countries); (5) estimates from na-
tional incidence estimates using modeled survival (83 countries);
and (6) rates are those of neighboring countries or registries in the
same area (three countries).8
2.4. HDI
HDI is a composite measure of indicators along three compo-
nents, including life expectancy, educational attainment, and
command over the resources needed for a decent living. All groups
and regions have seen notable improvement in all HDI components,
with faster progress in low- and medium-HDI countries. On this
basis, the world is becoming less unequal. Nevertheless, national
averages hide large variations in human experience. Wide dispar-
ities remain within developing and developed countries and in-
come inequality within and among many countries has been rising.
According to the HDI, countries are divided into four categories:
very high HDI ( 0.80), high HDI (0.80 > HDI > 0.710), medium HDI
(0.710  HD  0.535), and low HDI (<0.535).28
2.5. Statistical analysis
In this study, we used the correlation bivariate method for
assessment of the correlation between age-speciﬁc incidence and
mortality rate with HDI and its details, which include life expec-
tancy at birth, mean years of schooling, and gross national income
per capita. Statistical signiﬁcance was assumed at P < 0.05. All re-
ported P values were two-sided. Statistical analyses were per-
formed using SPSS Inc Version 18.0 (Chicago).
3. Results
In total, 1,094,916 cases of prostate cancer were recorded
worldwide in 2012. The following 10 countries had the highest
number of recent cases: United States (US) 233,159 cases; Brazil
72,536 cases; Germany 68,262 cases; France (metropolitan) 56,841
cases; Japan 55,970 cases; China 46,745 cases; United Kingdom
45,406 cases; Italy 44,525 cases; Spain 27,853 cases; and Canada
27,087. These countries account for 678,384 cases (61.95%) of the
global total.
The following 10 countries had the highest SIR of prostate
cancer: France 129.7 per 100,000 people; Martinique 123.1 per
100,00; Norway 227.2 per 100,000; Trinidad and Tobago 115.2 per
100,000; Barbados 123.9 per 100,000; Sweden and Ireland 114.6
per 100,000; Australia 119 per 100,000; New Caledonia 107.2 per
100,000; French Polynesia 114.9 per 100,000; and Switzerland
114.2 per 100,000. The following 10 countries had the lowest SIR of
prostate cancer: Uzbekistan 1.7 per 100,000 people; Bhutan 1.2 per
100,000; Nepal 1.5 per 100,000; Uzbekistan 2.0 per 100,000;
Turkmenistan 2.1 per 100,000; Tajikistan 2.3 per 100,000; Yemen
with 2.7 per 100,000; Sri Lanka 3.0 per 100,000; North Korea 3.2
per 100,000; and 3.4 per 100,000.
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human development regions; 37.5 per 100,000 in high human
development regions; 7.0 per 100,000 in medium human devel-
opment regions; and 14.9 per 100,000 in low human development
regions. Also, SIR was 58.5 per 100,000 people in the World Health
Organization (WHO) Europe Region; 75 per 100,000 in the WHO
Americas Region; 12.6 per 100,000 in the WHO Western Paciﬁc
Region; 9.7 per 100,000 in the WHO South-East Asia Region; and
26.8 per 100,000 in the WHO Africa Region. Also, it was 68 per
100,000 people in more-developed regions and 14.5 per 100,000 in
less-developed areas.
The number of cases and crude SIR of prostate cancer in
different regions of the world is shown in Table 1. Different parts of
the world are sorted from high to low according to SIR. The highest
and lowest standardized regions can be observed for each sex
(Figs. 1e2 and Table 1).
In the year 2012, 307,481 deaths occurred from prostate cancer
worldwide. Mortality was highest in the following 10 countries: US
30,383 cases; China 22,603 cases; Brazil 17,218 cases; Germany
12,548 cases; India 2,231 cases; Japan 1,164 cases; Russian Feder-
ation 11,480 cases, United Kingdom 10,595 cases; Nigeria 9,628Table 1
Number and rate of crude and standardized incidence and mortality of prostate cancer w
Prostate e estimated incidence, all ages
Population No. Crude rate ASR (W)
Australia/New Zealand 25,296 185.7 111.6
Oceania 26,130 138.3 101.9
North America 260,336 150.2 97.2
Western Europe 161,881 174.2 85.8
Northern Europe 81,696 165.4 85.0
Polynesia 227 65.1 81.9
Caribbean 18,719 89.3 79.8
WHO Americas Region 412,739 87.6 75.0
Micronesia/Polynesia 352 56.3 72.3
Very high human development 734,128 129.0 72.0
European Union (EU-28) 345,195 139.0 70.4
More developed regions 741,966 122.4 68.0
Southern Africa 10,266 35.3 61.7
Europe 400,364 112.0 61.3
South America 114,701 58.0 60.1
Micronesia 125 45.2 60.0
Southern Europe 91,355 118.0 58.6
WHO Europe Region 419,915 96.1 58.5
Latin America and Caribbean 152,403 51.2 54.2
IARC membership (24 countries) 790,747 60.2 50.2
High human development 195,839 38.2 37.5
Central and Eastern Europe 65,432 47.5 31.3
World 1,094,916 30.8 30.6
Central America 18,983 24.0 28.4
Western Asia 21,829 17.6 28.0
Sub-Saharan Africa 51,945 12.0 27.9
Middle Africa 6,892 10.4 27.0
WHO Africa Region 51,689 11.8 26.8
Western Africa 17,600 10.9 25.1
Eastern Africa 17,187 9.8 23.3
Africa 59,493 11.1 23.2
Melanesia 482 10.4 22.7
Middle-East and Northern Africa 29,377 12.9 19.7
Low human development 47,809 7.3 14.9
Less developed regions 352,950 12.0 14.5
WHO Western Paciﬁc Region 153,167 16.2 12.6
South-Eastern Asia 26,451 8.8 11.2
Northern Africa 7,548 7.3 10.6
Eastern Asia 118,583 14.5 10.5
WHO East Mediterranean Region 18,585 5.8 9.7
Asia 196,190 9.0 9.4
Medium human development 115,942 6.4 7.0
WHO South-East Asia Region 38,515 4.1 5.5
South-Central Asia 29,327 3.2 4.5
ASR (W), age-standardized rate (world); IARC, International Agency for Research on Cancases; and Indonesia 919 cases; giving a total of 147,521 fatal cases
(47.97%).
The following 10 countries had the highest SMR for prostate
cancer: Trinidad and Tobago 58.9 per 100,000 people; Guyana 48.2
per 100,000; Barbados 45.6 per 100,000; Burundi 40.2 per 100,000;
Jamaica 40.2 per 100,000; Uganda 38.8 per 100,000; Bahamas 36.6
per 100,000; Dominican Republic 34.6 per 100,000; Haiti 32.3 per
100,000; and Guinea 30.2 per 100,000. The following countries had
the lowest SMR for prostate cancer: Bhutan 0.7 per 100,000 people;
Nepal 1.2 per 100,000; Bangladesh 1.2 per 100,000; North Korea 1.3
per 100,000; Turkmenistan 1.5 per 100,000; Uzbekistan 1.5 per
100,000; Sri Lanka 1.6 per 100,000; Tajikistan 1.9 per 100,000; and
Yemen 2.3 per 100,000.
SMR based on HDI was 9.7 per 100,000 people in very high
human development regions; 12.9 per 100,000 in high human
development regions; 3.7 per 100,000 in medium human devel-
opment regions; and 12.1 per 100,000 in low human development
regions. Also, SIR was 11.5 per 100,000 people in the WHO Europe
Region; 13.1 per 100,000 in the WHO Americas Region; 3.5 per
100,000 in the WHOWestern Paciﬁc Region; 3.6 per 100,000 in the
WHO South-East Asia Region; 6.2 per 100,000 in the WHO Eastorldwide, in 2012.
Prostate e estimated mortality, all ages
Population No. Crude rate ASR (W)
Caribbean 7,970 38.0 29.3
Southern Africa 3,759 12.9 24.4
Middle Africa 5,900 8.9 24.2
Western Africa 14,277 8.8 21.2
Sub-Saharan Africa 37,802 8.7 20.9
WHO Africa Region 37,486 8.5 19.9
Eastern Africa 13,866 7.9 18.7
Africa 42,802 8.0 17.0
Latin America and Caribbean 51,313 17.2 16.6
South America 34,386 17.4 16.6
Polynesia 43 12.3 15.1
Northern Europe 18,099 36.7 14.5
Micronesia/Polynesia 67 10.7 13.7
Melanesia 253 5.4 13.3
Western Asia 10,422 8.4 13.1
WHO Americas Region 85,425 18.1 13.1
Oceania 4,250 22.5 13.0
High human development 72,623 14.2 12.9
Australia/New Zealand 3,930 28.9 12.9
Central America 8,957 11.3 12.1
Low human development 39,096 6.0 12.1
Micronesia 24 8.7 11.9
Central and Eastern Europe 25,862 18.8 11.6
WHO Europe Region 101,419 23.2 11.5
Europe 92,328 25.8 11.3
European Union (EU-28) 71,789 28.9 10.9
Western Europe 28,138 30.3 10.7
Middle-East and Northern Africa 15,422 6.8 10.2
More developed regions 142,014 23.4 10.0
North America 34,112 19.7 9.8
Very high human development 131,685 23.1 9.7
Southern Europe 20,229 26.1 9.1
IARC membership (24 countries) 157,081 12.0 8.4
World 307,481 8.6 7.8
Northern Africa 5,000 4.8 7.0
South-Eastern Asia 15,841 5.3 6.7
Less developed regions 165,467 5.6 6.6
WHO East Mediterranean Region 12,141 3.8 6.2
Asia 82,676 3.8 3.8
Medium human development 63,739 3.5 3.8
WHO South-East Asia Region 24,932 2.6 3.6
WHO Western Paciﬁc Region 45,977 4.9 3.5
Eastern Asia 37,553 4.6 3.1
South-Central Asia 18,860 2.0 2.9
cer.
Fig. 1. Standardized incidence and mortality rate of prostate cancer worldwide in 2012. ASR (W), age-standardised rate (world).
Fig. 2. Geographical distribution of prostate cancer incidence rate worldwide in 2012 (extracted from GLOBOCAN 2012). ASR, age-standardised rate.
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Region. SMR was 10.0 per 100,000 people in more-developed re-
gions and 6.6 per 100,000 in less-developed regions (Figs. 1,3 and
Table 1).
3.1. SIR and HDI
A positive correlation of 0.475 was seen between SIR of pros-
tate cancer and HDI and this correlation was statistically signiﬁ-
cant (P  0.001) (Fig. 4). Also, there was a positive correlationbetween HDI components and SIR. Between SIR and life expec-
tancy at birth, there was a positive correlation of 0.289 (P 0.001);
between SIR and mean education years, there was a positive cor-
relation of 0.422 (P  0.001); and between SIR and income level
per person in the population, there was a positive correlation of
0.353 (P  0.001).
Countries were classiﬁed according to HDI as follows: 47 in the
very high human development category; 46 in the high human
development category; 46 countries in the medium human
development category; 44 countries in the low human
Fig. 3. Geographical distribution of prostate cancer mortality rate worldwide in 2012 (extracted from GLOBOCAN 2012). ASR, age-standardised rate.
Prostate Int 4 (2016) 118e124122development category; and 8 countries in the unknown category.
Table 2 shows the numbers that were related to HDI and their
components.3.2. SMR and HDI
There was a negative correlation of 0.160 between SMR for
prostate cancer and HDI and it was statistically signiﬁcant
(P ¼ 0.032) (Fig. 5). Also, correlations were observed between HDI
components and standardized incidence. Between SMR and life
expectancy at birth, there was a negative correlation of 0.155
(P ¼ 0.038); between SMR and mean education years, there was a
negative correlation of 0.120 (P¼ 0.108); and between income levelFig. 4. Correlation between HDI and standardized incidence rate of prostate cancer
worldwide in 2012. HDI, Human Development Index.per person in the population, there was a negative correlation of
0.109 (P ¼ 0.145).4. Discussion
The results of this study showed that the exclusive incidence
rate of prostate cancer has a signiﬁcant and direct relationwith HDI
worldwide. Also, all components of HDI (life expectancy at birth,
education level, and income level) were related to the incidence of
cancer. Countries like France and Norway that had the highest age-
speciﬁc incidence and mortality rate of prostate cancer were
counted as high HDI countries and countries such as Bhutan and
Nepal that had the lowest incidence and mortality were counted as
low HDI countries. Other studies have also shown higher incidence
of prostate cancer in high HDI countries.4,17,29 The reasons may
include diet, lifestyle, widespread clinical examinations, and most
importantly, access to preventive services like PSA testing, and the
presence of cancer registry systems in countries with higher HDI.
One of the human development components that had a positive
and signiﬁcant relation with incidence of prostate cancer in this
studywas life expectancy at birth. Studies have shown that prostate
cancer has a close relationship with age, such that many cases occur
in men aged >80 years.30 Those living in countries with a greater
life expectancy relevant to the development indicators are more
likely to have cancer, including prostate cancer.31,32 This is related
to a decrease in communicable diseases and increase in treatment
methods of other diseases, and as a result, enhancement of life
expectancy and confrontation with old-age-related diseases like
prostate cancer.33
Another component of human development is education and
awareness. Results of this study showed that therewas a signiﬁcant
positive association with prostate cancer incidence. People who
have a higher education level have better diets, more physical ac-
tivity, and are less affected by communicable diseases, and the
chance of being affected by noncommunicable disease increases.34
Table 2
Human Development Index in 2012.
Population Human Development Index Life expectancy at birth (y) Mean years of schooling Gross national income per capita (US$)
Human Development Index groups
Very high human development 0.905 80.1 11.5 33,391
High human development 0.758 73.4 8.8 11,501
Medium human development 0.640 69.9 6.3 5,428
Low human development 0.466 59.1 4.2 1,633
Regions
Arab States 0.652 71.0 6.0 8,317
East Asia and Paciﬁc 0.683 72.7 7.2 6,874
Europe and Central Asia 0.771 71.5 10.4 12,243
Latin America and the Caribbean 0.741 74.7 7.8 10,300
South Asia 0.558 66.2 4.7 3,343
Sub-Saharan Africa 0.475 54.9 4.7 2,010
Least developed countries 0.449 59.5 3.7 1,385
Small island developing states 0.648 69.8 7.3 5,397
World 0.694 70.1 7.5 10,184
Hassanipour-Azgomi et al / Prostate cancer and Human Development Index in the worldwide 123In a study performed in the US, the incidence of prostate cancer in
educated men was greater than in the less educated population.35
The third part of HDI is sufﬁcient income, which is related to
gross domestic product. This study showed positive and signiﬁcant
relationships between gross domestic product and prostate cancer.
As high-income countries have better access to preventive and
treatment services, the diagnosis of illness is higher and they show
higher incidence.36,37 In this study, more access to screening for PSA
was related to socioeconomic level and income.38,39
The results of this study showed a signiﬁcant negative correla-
tion between SMR of prostate cancer and HDI. However, this rela-
tionship was different for various components of HDI as it was only
signiﬁcant for life expectancy with no signiﬁcant relationship
observed in the number of education years and income level.
The countries with the highest SMR for prostate cancer included
ﬁve in North America and the Caribbean (Trinidad and Tobago,
Barbados, Jamaica, Bahamas, Dominican Republic, and Haiti); three
in Africa (Burundi, Uganda, and Guinea), and one in South America
(Guyana). None of these countries are counted as very high HDI
countries.17 The noticeable point about these countries is that in
terms of cultural characteristics, socioeconomic status, dietary
habits, tobacco use, and access to preventive and treatment ser-
vices, they are at the same level as countries in similar regions, andFig. 5. Correlation between HDI and standardized mortality rate of prostate cancer
worldwide in 2012. HDI, Human Development Index.this may explain the high mortality of prostate cancer in the
geographical regions surrounding these countries.
As mentioned earlier, the only HDI component that had a sig-
niﬁcant relationship with SMR for prostate cancer was life expec-
tancy at birth. Among the 10 countries with the highest prostate
cancer mortality, the best life expectancy was in Barbados, with
78 years.17 In comparison with cancer exclusive incidence, that is,
more frequently seen in high HDI countries, we can say that care,
treatment, and patient survival in high HDI countries are better,
cancer is diagnosed at a younger age when the disease is still in its
primary stages, and prognosis is better. Conversely, in low HDI
countries, the disease is diagnosed in older men and at a more
advanced stage, which results inworse prognosis, less surveillance,
and higher mortality.13,40,41
The results of the survey did not show signiﬁcant correlation,
except for the level of education and mortality of prostate cancer,
which was in line with the ﬁndings of Pakzad et al4 in Asian
countries. In a study performed in the US, people who were
educated for < 12 years in comparison with those educated for
> 12 years showed higher SMR.42
The present study did not show a signiﬁcant relationship be-
tween level of income and SMR for prostate cancer, which was
similar to other studies in this ﬁeld.4 Other studies in this context
did not present a linear and ﬁxed procedure and we cannot speak
with certainty about the relationship between income levels and
mortality of prostate cancer.
This study had some limitations. This study was an ecological
study and the limitations include ecological fallacy and lack of
correlation between group and individual results.
In conclusion, the incidence of prostate cancer is higher in
countries that are more developed. A positive correlation was
observed between the SIR of prostate cancer and HDI and its
components, such as life expectancy at birth, mean years of
schooling, and income level per person of the population. In
addition, there was a negative correlation between the SMR and
HDI. Epidemiological transition is expected to occur in commu-
nities with increasing HDI and reduced incidence of infectious
diseases and increased incidence of noncommunicable diseases
such as cancer. However, although the incidence is high, the mor-
tality rate is reduced, which represents an improvement of diag-
nosis and efﬁcacy of treatment in prostate cancer patients with
increasing levels of HDI.Conﬂicts of interest
None declared.
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